Drugs / AMG 319
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01300026 | Apr 2011 → Oct 2013 | B-cell chronic lymphocytic leukemia, T-cell non-Hodgkin lymphoma, cancer, diffuse large B-cell lymphoma +1 | Amgen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02540928 | Oct 2015 → May 2018 | head and neck squamous cell carcinoma, human papilloma virus infection | Cancer Research UK | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01300026 ↗ |
| Known as | J3.391.906I | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303596 ↗ |
| Action | Inhibit | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4303596 ↗1“small molecule inhibitor of PI3Kδ” NCT01300026 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT01300026 ↗ |
| Route | Oral | “administered by mouth once daily” NCT01300026 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4303596 ↗ |